Sevelamer and CKD-associated cardiovascular disease: going further, but far from there

Area of Science:

• Nephrology and Cardiovascular Medicine
• Mineral Metabolism and Bone Disease

Background:

• Cardiovascular disease (CVD) is a significant complication in chronic kidney disease (CKD).
• Mineral metabolism disturbances are strongly linked to CVD in CKD patients.
• The therapeutic impact of treating CKD-mineral and bone disorder (CKD-MBD) on cardiovascular outcomes remains debated.

Purpose of the Study:

• To investigate the effects of sevelamer, a phosphate binder, on cardiovascular complications in a mouse model of CKD.
• To assess sevelamer's impact on aortic stiffness, endothelial function, and cardiac structure and function.

Main Methods:

• A mouse model of CKD was established.
• Mice were treated with sevelamer.
• Aortic stiffness, endothelial function, left ventricular function, and hypertrophy were evaluated.

Main Results:

• Sevelamer treatment demonstrated benefits in reducing the progression of aortic stiffness.
• The study observed improvements in endothelial dysfunction in mice treated with sevelamer.
• Sevelamer also showed positive effects on left ventricular dysfunction and hypertrophy.

Conclusions:

• Sevelamer, a phosphate binder, may offer protective effects against cardiovascular complications in CKD.
• Therapeutic interventions targeting mineral metabolism disturbances could potentially mitigate cardiovascular burden in CKD.
• Further research is warranted to confirm these findings in human CKD populations.